Hyaluronidase Power Injection Market size is expected to reach USD 2 Billion by the end of 2036, growing at a CAGR of over 9% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of hyaluronidase power injection was around USD 910 Million. The increasing acuteness across different application fields will act as the primary driver that will drive the market of hyaluronidase power injection and will take it to the anticipated CAGR. For instance, the degradation kinetics of the TEOSYAL RHA accumulation, manufactured by TEOXANE SA (Geneva, Switzerland), is implementing the maintained network technology (PNT) to use in different applications. In humans, six different hyaluronidases, HYAL1-4, HYAL-P1, and PH-20, have been identified. Hyaluronidase looks for applications in cosmetic therapies, cancer treatment, and ophthalmic therapeutic solutions.
Additionally, the increasing number of nominally invasive aesthetic surgeries is calculated to amplify the hyaluronidase power injection system's demand in the forecast period. For instance, The International Society of Aesthetic Plastic Surgery (ISAPS) announced the results of its yearly Global Survey on Aesthetic/Cosmetic Procedures this week at the ISAPS Olympiad Athens World Congress 2023, which rounded up more than 1,000 attendees from 90 countries to talk about the newest scientific research, novelties, and processes to modify patient protection in aesthetic plastic surgery. The report demonstrates an 11.2% complete rise in techniques executed by plastic surgeons in 2022 with more than 14.9 million surgical and 18.8 million non-surgical techniques executed across the world. Liposuction was the most general surgical technique in 2022 as in 2021, with more than 2.3 million techniques and a 21.1% rise.
Growth Drivers
Challenges
|
Base Year |
2023 |
|
Forecast Year |
2036 |
|
CAGR |
∼9% |
|
Base Year Market Size (2023) |
~USD 910 Million |
|
Forecast Year Market Size (2036) |
~USD 2 Billion |
|
Regional Scope |
|
Source (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase, Bio-Engineered Hyaluronidase)
The animal-derived hyaluronidase segment in the hyaluronidase power injection market is projected to hold its position with over 55% of revenue share by the end of the predicted timeline. It is because most licensed and advertised brands, at present, are taken from animal sources, and the most commonly implemented animal sources are bovine and porcine products. To illustrate, the US FDA has approved the recombinant human hyaluronidase PH20 (rHuPH20) which works locally to provisionally eliminate the glycosaminoglycan hyaluronan’s barrier, enabling quick subcutaneous (SC) submission of large volumes and/or high doses of successively or co-directed therapeutics. Moreover, the animal-derived hyaluronidase market has witnessed a substantial number of product approvals, contributing to the massive demand for the animal-derived hyaluronidase segment in the coming years.
Application (Dermatology, Chemotherapy, Ophthalmology, Plastic Surgery, Cosmetology)
Hyaluronidase power injection market from the dermatology segment held the largest profit share in 2023 and is estimated to hold this position with approximately 45% revenue share by the end of 2036. The increasing importance of hyaluronidase power injections’ safety in dermatology has resulted in the highest profit production. In December 2021, a research study released by the American Society for Dermatologic Surgery (ASDA) expressed that hyaluronic acid fillers VYC-20I were harmless and efficient for cheek augmentation via cannula and noninferior to needle injection. Utilizing cannulas to provide facial fillers may limit negative events (AEs) in comparison with needle injection. The setup of a standard technique is anticipated to modify the momentum of market expansion in the future.
Our in-depth analysis of the global hyaluronidase power injection market includes the following segments:
|
Source |
|
|
Application |
|
|
Distribution Channels |
|
North American Market Statistics
North American region is expected to account for 30% share of the global hyaluronidase power injection market by 2036. This is due to the increasing number of experimental procedures that present an in-vitro assessment of the biological attainability of hyaluronidase and the appearance of key players producing these products in the region. According to The American Society of Plastic Surgeons (ASPS), the globe's largest plastic surgery company, symbolizing 92 percent of all board-certified plastic surgeons in the United States data released in 2022, there were 26.2 million surgical and minimally invasive cosmetic and reconstructive techniques experimented as well as executed in the United States in 2022. More particularly, there has been a 19% surge in cosmetic surgery techniques since 2019. Moreover, the high adoption of progressed therapy choices and an acknowledgeable number of dermatology clinics advocating such therapies contribute to immense market expansion across North America.
APAC Market Analysis
Asia Pacific hyaluronidase power injection market is projected to expand at the quickest CAGR during the forecast period and is set to hold the position of second largest shareholder with almost 26% profit share. This growth is wheeled as a result of medical tourism for dermatology therapies and dermatological device applications in different countries of the region. In line with the Korea Health Industry Development Institute, the number of medical tourists exploring South Korea increased eightfold in ten years—from 60,000 in 2011 to almost half a million in 2021. Overseas patients now make up almost half of all plastic surgeries executed in South Korea. In addition, the presence of a significant number of suppliers together with the emergence of technologies in South Korea is further anticipated to drive the market expansion.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?